Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: Studies in MMTV-cortactin and MMTV-cortactin/-cylin DI bitransgenic mice

BMC Cancer

Volumn 6, Issue , 2006, Pages

  van Rossum, Agnes G S H ^a,b   van Bragt, Maaike P A ^a   Schuuring Scholtes, Ellen ^a   van der Ploeg, Jan C M ^a   van Krieken, Johan H J M ^c   Kluin, Philip M ^a,d   Schuuring, Ede ^a,d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTACTIN; CYCLIN D1; EOSIN; HEMATOXYLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; BREAST HYPERPLASIA; BREAST TUMOR; BREEDING; CANCER INCIDENCE; CHROMOSOME 11Q; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC CROSS; IMMUNOHISTOCHEMISTRY; MAMMARY GLAND; METASTASIS; MICROSCOPY; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; MULTIPARA; NONHUMAN; NORTHERN BLOTTING; ONSET AGE; PRECANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; STATISTICAL ANALYSIS; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE;

ANIMALS; CORTACTIN; CYCLIN D1; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; PRECANCEROUS CONDITIONS;

EID: 33646234748     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-58     Document Type: Article

References (45)

1. Siesling S, van Dijck JA, Visser O, Coebergh JW: Trends in incidence of and mortality from cancer in The Netherlands in the period 1989-1998. Eur J Cancer 2003, 39:2521-2530.
2. Hui R, Ball JR, Macmillan RD, Kenny FS, Prall OW, Campbell DH, Cornish AL, McClelland RA, Daly RJ, Forbes JF, Blamey RW, Musgrove EA, Robertson JF, Nicholson RI, Sutherland RL: EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 1998, 17:1053-1059.
3. Lammie GA, Fantl V, Smith R, Schuuring E, Brookes S, Michalides R, Dickson C, Arnold A, Peters G: D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991, 6:439-444.
4. Schuuring E, Verhoeven E, van Tinteren H, Peterse JL, Nunnink B, Thunnissen FB, Devilee P, Cornelisse CJ, van de Vijver MJ, Mooi WJ: Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 1992, 52:5229-5234.
5. Campbell DH, deFazio A, Sutherland RL, Daly RJ: Expression and tyrosine phosphorylation of EMS1 in human breast cancer cell lines. Int J Cancer 1996, 68:485-492.
6. Schuuring E, Verhoeven E, Mooi WJ, Michalides RJ: Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 1992, 7:355-361.
7. Patel AM, Incognito LS, Schechter GL, Wasilenko WJ, Somers KD: Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines. Oncogene 1996, 12:31-35.
8. Arnold A: The cyclin D1/PRAD1 oncogene in human neoplasia. J Investig Med 1995, 43:543-549.
9. Hosokawa Y, Arnold A: Cyclin D1/PRAD1 as a central target in oncogenesis. J Lab Clin Med 1996, 127:246-252.
10. Sherr CJ: Cancer cell cycles. Science 1996, 274:1672-1677.
11. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993, 8:2127-2133.
12. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994, 57:353-361.
13. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994, 54:1812-1817.
14. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994, 369:669-671.
15. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P: Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 1989, 57:931-936.
16. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987, 49:465-475.
17. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54:105-115.
18. Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature 2001, 411:1017-1021.
19. Uruno T, Liu J, Zhang P, Fan Y, Egile C, Li R, Mueller SC, Zhan X: Activation of Arp2/3 complex-mediated actin polymerization by cortactin. Nat Cell Biol 2001, 3:259-266.
20. Weed SA, Karginov AV, Schafer DA, Weaver AM, Kinley AW, Cooper JA, Parsons JT: Cortactin localization to sites of actin assembly in lamellipodia requires interactions with F-actin and the Arp2/3 complex. J Cell Biol 2000, 151:29-40.
21. Daly RJ: Cortactin signalling and dynamic actin networks. Biochem J 2004, 382:13-25.
22. Patel AS, Schechter GL, Wasilenko WJ, Somers KD: Overexpression of EMS1/ cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene 1998, 16:3227-3232.
23. Huang C, Liu J, Haudenschild CC, Zhan X: The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem 1998, 273:25770-25776.
24. van Rossum AG, De Graaf JH, Schuuring-Scholtes E, Kluin PM, Fan YX, Zhan X, Moolenaar WH, Schuuring E: Alternative splicing of the actin binding domain of human cortactin affects cell migration. J Biol Chem 2003, 278:45672-45679.
25. Li Y, Tondravi M, Liu J, Smith E, Haudenschild CC, Kaczmarek M, Zhan X: Cortactin potentiates bone metastasis of breast cancer cells. Cancer Res 2001, 61:6906-6911.
26. Bishop JM: Molecular themes in oncogenesis. Cell 1991, 64:235-248.
27. Hunter T, Pines J: Cyclins and cancer. Cell 1991, 66:1071-1074.
28. Compagni A, Christofori G: Recent advances in research on multistage tumorigenesis. Br J Cancer 2000, 83:1-5.
29. Schuuring E, Verhoeven E, Litvinov S, Michalides RJ: The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell- substratum contact sites. Mol Cell Biol 1993, 13:2891-2898.
30. Schuuring E, van Damme H, Schuuring-Scholtes E, Verhoeven E, Michalides R, Geelen E, de Boer C, Brok H, van BV, Kluin P: Characterization of the EMS1 gene and its product, human Cortactin. Cell Adhes Commun 1998, 6:185-209.
31. Morgenstern JP, Land H: A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res 1990, 18:1068.
32. Krimpenfort P, Berns A: Gene transfer into mammalian embryos. Hum Reprod 1987, 2:333-339.
33. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE: The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000, 19:968-988.
34. de Boer CJ, van Krieken JH, Kluin-Nelemans HC, Kluin PM, Schuuring E: Cyclin D1 messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene 1995, 10:1833-1840.
35. van Rossum AG, Moolenaar WH, Schuuring E: Cortactin affects cell migration by regulating intercellular adhesion and cell spreading. Exp Cell Res 2006 in press.
36. Mahler JF, Stokes W, Mann PC, Takaoka M, Maronpot RR: Spontaneous lesions in aging FVB/N mice. Toxicol Pathol 1996, 24:710-716.
37. Helwani FM, Kovacs EM, Paterson AD, Verma S, Ali RG, Fanning AS, Weed SA, Yap AS: Cortactin is necessary for E-cadherin-mediated contact formation and actin reorganization. J Cell Biol 2004, 164:899-910.
38. El Sayegh TY, Arora PD, Laschinger CA, Lee W, Morrison C, Overall CM, Kapus A, McCulloch CA: Cortactin associates with N-cadherin adhesions and mediates intercellular adhesion strengthening in fibroblasts. J Cell Sci 2004, 117:5117-5131.
39. Kitsberg DI, Leder P: Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene 1996, 13:2507-2515.
40. Ma ZQ, Chua SS, DeMayo FJ, Tsai SY: Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B. Oncogene 1999, 18:4564-4576.
41. Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR, Roderick TH, Stewart CL, Lilly F, Hansen CT: FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci U S A 1991, 88:2065-2069.
42. Nieto AI, Shyamala G, Galvez JJ, Thordarson G, Wakefield LM, Cardiff RD: Persistent mammary hyperplasia in FVB/N mice. Comp Med 2003, 53:433-438.
43. Wakefield LM, Thordarson G, Nieto AI, Shyamala G, Galvez JJ, Anver MR, Cardiff RD: Spontaneous pituitary abnormalities and mammary hyperplasia in FVB/NCr mice: implications for mouse modeling. Comp Med 2003, 53:424-432.
44. Hennighausen L, Robinson GW: Think globally, act locally: the making of a mouse mammary gland. Genes Dev 1998, 12:449-455.
45. Hosokawa Y, Papanikolaou A, Cardiff RD, Yoshimoto K, Bernstein M, Wang TC, Schmidt EV, Arnold A: In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53. Transgenic Res 2001, 10:471-478.